Although effective in treating other varieties of BRAFV600E malignancies, tolerance towards BRAFi as a monotherapy has been shown in melanoma and HGG, commonly through (acquired, secondary) reactivation of the MEK pathway in melanoma, and resistance mechanisms are discussed in more detail below. Here, MAP2K7 is linked to melanoma.